906 related articles for article (PubMed ID: 14518718)
1. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
3. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
[TBL] [Abstract][Full Text] [Related]
4. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection.
Coppola N; Pisapia R; Tonziello G; Martini S; Imparato M; Piai G; Stanzione M; Sagnelli C; Filippini P; Piccinino F; Sagnelli E
Antivir Ther; 2008; 13(2):307-18. PubMed ID: 18505182
[TBL] [Abstract][Full Text] [Related]
5. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination.
Ohara T; Oteki T; Suzuki T; Suzuki M; Matsuzaki Y
Hepatogastroenterology; 2011; 58(105):133-6. PubMed ID: 21510300
[TBL] [Abstract][Full Text] [Related]
7. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
[TBL] [Abstract][Full Text] [Related]
8. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy.
Saitta C; Pontisso P; Brunetto MR; Fargion S; Gaeta GB; Niro GA; Picciotto A; Smedile A; Squadrito G; Raimondo G
Antivir Ther; 2006; 11(7):931-4. PubMed ID: 17302256
[TBL] [Abstract][Full Text] [Related]
9. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
Uyanikoglu A; Akyuz F; Baran B; Simsek BP; Ermis F; Demir K; Gulluoglu M; Badur S; Kaymakoglu S
Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):485-90. PubMed ID: 23665172
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
[TBL] [Abstract][Full Text] [Related]
11. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
Cacciola I; Pollicino T; Squadrito G; Cerenzia G; Orlando ME; Raimondo G
N Engl J Med; 1999 Jul; 341(1):22-6. PubMed ID: 10387938
[TBL] [Abstract][Full Text] [Related]
12. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C.
Fabris P; Brown D; Tositti G; Bozzola L; Giordani MT; Bevilacqua P; de Lalla F; Webster GJ; Dusheiko G
J Clin Virol; 2004 Mar; 29(3):160-6. PubMed ID: 14962784
[TBL] [Abstract][Full Text] [Related]
13. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C.
Mrani S; Chemin I; Menouar K; Guillaud O; Pradat P; Borghi G; Trabaud MA; Chevallier P; Chevallier M; Zoulim F; Trépo C
J Med Virol; 2007 Aug; 79(8):1075-81. PubMed ID: 17596829
[TBL] [Abstract][Full Text] [Related]
14. Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander?
Chu CJ; Lee SD
J Gastroenterol Hepatol; 2010 Feb; 25(2):221-3. PubMed ID: 20136983
[No Abstract] [Full Text] [Related]
15. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin.
Levast M; Larrat S; Thelu MA; Nicod S; Plages A; Cheveau A; Zarski JP; Seigneurin JM; Morand P; Leroy V
J Med Virol; 2010 May; 82(5):747-54. PubMed ID: 20336715
[TBL] [Abstract][Full Text] [Related]
17. The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients.
Silva Cd; Gonçales NS; Pereira JS; Escanhoela CA; Pavan MH; Gonçales FL
Braz J Infect Dis; 2004 Dec; 8(6):431-9. PubMed ID: 15880234
[TBL] [Abstract][Full Text] [Related]
18. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
19. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
20. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
